Market Place
Sourcing Support
Jazz`s almost-withdrawn lung cancer drug shows life
16 Oct 2024 //
PR NEWSWIRE
Genprex Receives Approval To Advance In Acclaim-3 Trial
15 Oct 2024 //
PR NEWSWIRE
Oncocyte’s DetermaIO Response to Atezolizumab in Ph 2 Trial
08 Oct 2024 //
GLOBENEWSWIRE
Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan
17 Sep 2024 //
FIERCE PHARMA
Exelixis Presents CONTACT-02 Results For Cabozantinib Combo At ESMO
15 Sep 2024 //
BUSINESSWIRE
Ipsen Updates On CONTACT-02 Trial In Prostate Cancer After Final Analysis
15 Sep 2024 //
GLOBENEWSWIRE
Roche`s Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
14 Sep 2024 //
FIERCE PHARMA
FDA Approves Roche`s Subcutaneous Cancer Immunotherapy Tecentriq Hybreza
13 Sep 2024 //
GLOBENEWSWIRE
FDA Approves Genentech`s Subcutaneous Cancer Immunotherapy
12 Sep 2024 //
BUSINESSWIRE
Xilio Therapeutics Announces Q2 2024 Results And Pipeline Updates
08 Aug 2024 //
GLOBENEWSWIRE
Genentech Updates On Phase II/III SKYSCRAPER-06 Study In Lung Cancer
04 Jul 2024 //
BUSINESSWIRE
Tempest Unveils New Data For Amezalpat Showing Six-Month Improvement
20 Jun 2024 //
GLOBENEWSWIRE
Affimed`s AFM24 Combo Shows Durable Responses In Pretreated NSCLC
01 Jun 2024 //
GLOBENEWSWIRE
Affimed Gets Fast Track For AFM24-Atezolizumab In NSCLC
29 May 2024 //
GLOBENEWSWIRE
Affimed Early Efficacy Results: Afm24-102 Egfrwt Nsclc At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Xilio Provides Pipeline Updates, Q1 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
Genprex ExpandsTrial Sites for Acclaim-3 Study with Tecentriq to Treat SCLC
03 Apr 2024 //
PR NEWSWIRE
Gritstone ground down by phase 2 cancer vaccine fail
01 Apr 2024 //
FIERCE BIOTECH
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front
30 Jan 2024 //
FIERCE PHARMA
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
26 Jan 2024 //
ENDPTS
Roche’s Tecentriq SC receives EC approval for cancer treatment
17 Jan 2024 //
PHARMACEUTICAL TECHNOLOGY
Affimed Announces Positive Data for AFM24 in Combination with Atezolizumab
11 Dec 2023 //
GLOBENEWSWIRE
Oncolytics Announces Phase 1/2 Study of Pelareorep Has Met Criteria for Efficacy
09 Nov 2023 //
PR NEWSWIRE
Roche hits FDA delay with subcutaneous Tecentriq
07 Sep 2023 //
FIERCE PHARMA
Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in NSCLC
01 Sep 2023 //
ONCLIVE
England to rollout world-first seven-minute cancer treatment jab
30 Aug 2023 //
REUTERS
Halozyme Announces Approval of Roche`s Tecentriq® SC with ENHANZE
29 Aug 2023 //
PR NEWSWIRE
Roche reports inadvertent disclosure in lung cancer immunotherapy study
24 Aug 2023 //
GLOBENEWSWIRE
Sonnet Announces FDA Acceptance of IND for the SB221 Trial of SON-1010
16 Aug 2023 //
ACCESSWIRE
Tvardi doses first patients in REVERT Liver Cancer trial
23 Jun 2023 //
CLINICAL TRIALS ARENA
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter
23 Jun 2023 //
ONCOLIVE
Sonnet Announces Regulatory Approval for Initiation of a Trial of SON-1010
20 Jun 2023 //
ACCESSWIRE
ASCO: Merck`s Keytruda, Roche`s Tecentriq add to I-O failures
06 Jun 2023 //
FIERCE PHARMA
Patient deaths taint Roche`s landmark adjuvant liver cancer data
16 Apr 2023 //
FIERCE PHARMA
Omega Announces Agreement to Evaluate the Combination of OTX-2002
30 Mar 2023 //
GLOBENEWSWIRE
Roche, Exelixis` Tecentirq-Cabometyx fails a 3rd time
04 Mar 2023 //
FIERCE PHARMA
Exelixis Provides Update on PIII Trial Evaluating Cabozantinib with Atezolizumab
02 Mar 2023 //
BUSINESSWIRE
CARsgen Announces Agreement to Evaluate AB011 with PD-L1 to Treat Gastric Cancer
01 Feb 2023 //
PR NEWSWIRE
Keytruda wins broad adjuvant NSCLC nod to pressure Tecentriq
28 Jan 2023 //
PRESS RELEASE
Roche`s Tecentriq, Avastin combo cuts risk of liver cancer returning
20 Jan 2023 //
BIOPHARMADIVE
Rare cancer drug for young patients approved
03 Jan 2023 //
PHARMAFILE
NIH trial leads to atezolizumab approval for advanced alveolar soft part
30 Dec 2022 //
PHARMABIZ
Adagene to Collaborate to Evaluate Anti-CTLA-4 SAFEbody ADG126 with Roche
16 Dec 2022 //
GLOBENEWSWIRE
Roche wins earlier-than-expected approval for Tecentriq
14 Dec 2022 //
ENDPTS
Exelixis/Roche Combo Fails to Improve Overall Survival in NSCLC
10 Dec 2022 //
BIOSPACE
Ipsen Provides Update On PIII Trial Evaluating Cabozantinib With Atezolizumab
08 Dec 2022 //
BUSINESSWIRE
Replimune Enters into Clinical Collaboration Agreement with Roche
07 Dec 2022 //
GLOBENEWSWIRE
Genentech`s Biologic TECENTRIQ (Atezolizumab) Receives Approval in the U.S.
02 Dec 2022 //
FDA
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector
01 Dec 2022 //
BIONJ
Roche unwraps results of subcutaneous Tecentriq phase 3 trial
01 Dec 2022 //
FIERCEPHARMA
Roche pulls another FDA accelerated approval for cancer drug Tecentriq
30 Nov 2022 //
FIERCEPHARMA
Attralus doses first subject in Phase I pan-amyloid removal therapy trial
17 Oct 2022 //
CLINICALTRIALSARENA
Exelixis Announces Dose-Escalation Results from the PI STELLAR-001 Trial
10 Sep 2022 //
BUSINESSWIRE
Roche readies to file subq Tecentriq after posting phase 3 data
03 Aug 2022 //
FIERCEPHARMA
Roche trims out some pipeline failures while flagging a PhIII flop for Tecentriq
22 Jul 2022 //
ENDPTS
Galecto Begins Enrollment in Trial of GB1211 + Atezolizumab for 1L NSCLC
16 Jun 2022 //
GLOBENEWSWIRE
Individualised mRNA vaccine shows promise in pancreatic cancer patients
08 Jun 2022 //
EUROPEANPHARMACEUTICALREVIEW
ImaginAb, Roche have entered trial supply agreement for atezolizumab
08 Jun 2022 //
PRNEWSWIRE
Roche`s trial flop casts shadow on Big Pharma`s $6B TIGIT bet
17 May 2022 //
FIERCEBIOTECH
